Jaume Mora Graupera
Jefe de Grupo Senior
Research group
Professional network profiles
Last Publications
- CastilloSD, Perosanz X, Ressler AK, Ivars M, Rodriguez J, Rovira-Zurriaga C, Nola EM, Llena J, Grego-Bessa J, Roldan-Molina M, Arnau R, Martínez-Romero A, Barber-Martínez de la Torre I, Miguel Bejarano Serrano, Vicente-Villa MA, Celis-Passini V, Salvador-Hernandez H, Mora J, Marchuk DA, Baselga E and Graupera M Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome CANCER DISCOVERY . 15(7): 1350-1362.
- Baulenas-Farrés M, Paco-Mercader S, Marino F, Mohr J, Panisello C, Balaguer-Lluna L, Aschero MR, Cuadrado-Vilanova M, Resa-Parés C, Rodriguez E, Márquez-Pereira JM, Menéndez P, Jou-Munoz C, Benítez R, Benitez-Ribas D, Lavarino C, Mora J and Carcaboso AM Proteins of the cancer cell secretome induce the protumoral microenvironment of diffuse intrinsic pontine glioma. neuro-oncology advances . 7(1): .
- Balaguer-Lluna L, Gene-Olaciregui N, Aschero MR, Resa-Parés C, Paco-Mercader S, Cuadrado-Vilanova M, Burgeño-Sandoval V, Baulenas-Farrés M, Monterrubio C, Manzanares-Quintela A, Rodriguez E, Lavarino C, Mora J and Carcaboso AM Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas JOURNAL OF NEURO-ONCOLOGY . 172(3): 599-611.
Projects
- Project name:
- ADVANCED THERAPIES (RICORS-TERAV)
- Leader
- Susana Rives Solà
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- RD24/0014/0006
- Starting - finishing date:
- 2025 - 2027
- Project name:
- Disrupción de enhancers: la nueva generación de terapia epigenética en el sarcoma de Ewing
- Leader
- Jaume Mora Graupera, Sara Sánchez Molina
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI24/00804
- Starting - finishing date:
- 2025 - 2027
- Project name:
- Ensayo clínico de seguridad y factibilidad de inmunoterapia celular: Células dendríticas autólogas pulsadas con un lisado de líneas tumorales alogénicas, asociadas con CART anti-IL13Ra2 en pacientes con tumor difuso intrínseco de tronco (DIPG) (fase Ib)
- Leader
- Andrés Morales La Madrid
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- ICI23/00063
- Starting - finishing date:
- 2024 - 2027
News
-
The Josep Carreras Foundation and Sant Joan de Déu Create a Childhood Leukemia Research Program Worth Over 10 Million Euros
The Josep Carreras Foundation (FJC), the Josep Carreras Leukemia Research Institute (IJC), and the Sant Joan de Déu Research Institute (IRSJD) have agreed to develop a joint research program on childhood leukemia valued at over 10 million euros.
-
New discoveries about the EWS-FLI oncogene involved in the development of Ewing's tumor
Researchers from IRSJD · SJD Barcelona Children’s Hospital and IRB Barcelona have successfully developed Drosophila models expressing the EWS-FLI oncogene at varying levels, overcoming previous toxicity challenges and enabling detailed study of Ewing sarcoma's oncogenic pathways.
-
Researchers from IRSJD and IRB Barcelona unveil the origin of second pediatric cancers and chemotherapy-induced mutations in healthy tissues
A team from Institut de Recerca Sant Joan de Déu and IRB Barcelona has studied the cases of four children who have experienced two cancers during childhood and has addressed the origin of the second tumour. The work has been published in the journal Cancer Discovery.
More activities
-
Defensa tesi doctoral: Pablo Táboas Outón
Auditori Plaza · Hospital Sant Joan de Déu and online
-
Defensa tesi doctoral: Irene Cuervas Oliveras
Auditori Plaza · Hospital Sant Joan de Déu
-
Defensa tesi doctoral: María Sánchez Jiménez
Auditori Plaza · Hospital Sant Joan de Déu and online